IL-17/IL-23 Biologic Therapy: Understanding Psoriasis…

What IL-17/IL-23 Biologics Are

Biologic therapies are a class of medications that target specific proteins in the body. In the context of psoriasis, these drugs specifically target interleukins (IL), which are cytokines involved in immune responses and inflammation. IL-17 and IL-23 are two such cytokines that play crucial roles in the development of psoriatic lesions.

These biologics work by binding to their respective receptors on immune cells, thereby blocking the signaling pathways that lead to inflammation and skin cell overproduction, which are hallmarks of psoriasis.

How IL-17/IL-23 Biologics Work

By inhibiting IL-17 and IL-23, these biologics reduce the production of pro-inflammatory cytokines and chemokines. This results in a decrease in immune cell recruitment to the skin, reduced inflammation, and decreased proliferation of keratinocytes (skin cells).

The net effect is a reduction in psoriatic lesions, as evidenced by improvements in clinical measures such as the Psoriasis Area and Severity Index (PASI) score.

live demo · related simulation● LIVE

Therapeutic Outcomes

Clinical trials have shown that biologic therapies targeting IL-17 and IL-23 can lead to significant improvements in psoriasis symptoms. Patients often experience a reduction in the number and size of skin lesions, as well as an improvement in overall quality of life.

The PASI score is commonly used to quantify these changes. A lower PASI score indicates better therapeutic response.

Real-World Applications

These biologics are particularly beneficial for patients with moderate-to-severe psoriasis who do not respond adequately to traditional therapies or have contraindications. They can also be used in combination with other treatments for optimal results.

Examples of such biologics include Skyrizi (risankizumab), Cosentyx (secukinumab), and Taltz (ixekizumab).

Frequently asked questions

How do IL-17/IL-23 biologics differ from traditional psoriasis treatments?

Traditional treatments often focus on topical creams or systemic medications that broadly suppress the immune system. Biologic therapies, however, target specific cytokines like IL-17 and IL-23, providing more precise control over inflammation.

What are the potential side effects of these biologics?

Common side effects include injection site reactions, infections (due to immune suppression), and allergic reactions. More serious but less common risks may include reactivation of latent tuberculosis or other opportunistic infections.

How long does it take for IL-17/IL-23 biologics to show results?

Patients often start seeing improvements within weeks, though the full therapeutic effect can take several months. Response rates vary among individuals and may depend on the severity of psoriasis.

Are these treatments suitable for everyone with psoriasis?

Not all patients are candidates for biologic therapies due to factors such as active infections, certain medical conditions, or a history of severe allergic reactions. Doctors will assess individual cases before prescribing.

Try it live

Everything above runs in your browser — open IL-17/IL-23 Biologic Therapy Simulator and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.

▶ Open IL-17/IL-23 Biologic Therapy Simulator simulation

IL-17/IL-23 Biologic Therapy: Understanding Psoriasis Treatment